PHASE-II TRIAL OF TOPOTECAN IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA

被引：29

作者：

LAW, TM ^{[1
]}

ILSON, DH ^{[1
]}

MOTZER, RJ ^{[1
]}

机构：

[1] MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR ONCOL,GENITOURINARY ONCOL SERV,NEW YORK,NY 10021

来源：

INVESTIGATIONAL NEW DRUGS | 1994年 / 12卷 / 02期

关键词：

TOPOTECAN; RENAL CELL CARCINOMA;

D O I：

10.1007/BF00874445

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fifteen patients with advanced renal cell carcinoma were treated on a phase II trial with topotecan. None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the most common toxicity. Eighty percent (12 of 15) of patients experienced grade III or IV neutropenia and/or anemia. Topotecan is not efficacious in the treatment of advanced renal cell carcinoma.

引用

页码：143 / 145

页数：3

共 6 条

[1]

JAXEL C, 1989, CANCER RES, V49, P1465

[2]

JOHNSON R K, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P623

[3]

MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO

[4]

2-6

[5]

SIROTT MN, 1991, P AN M AM SOC CLIN, V10, P104

[6] THE CURRENT STATUS OF CAMPTOTHECIN ANALOGS AS ANTITUMOR AGENTS [J].

SLICHENMYER, WJ ;

ROWINSKY, EK ;

DONEHOWER, RC ;

KAUFMANN, SH .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (04) :271-291

← 1 →